| Product NDC: | 0179-0028 |
| Proprietary Name: | Stavudine |
| Non Proprietary Name: | Stavudine |
| Active Ingredient(s): | 40 mg/1 & nbsp; Stavudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0179-0028 |
| Labeler Name: | KAISER FOUNDATION HOSPITALS |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA078957 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20100127 |
| Package NDC: | 0179-0028-70 |
| Package Description: | 30 CAPSULE in 1 BOX, UNIT-DOSE (0179-0028-70) |
| NDC Code | 0179-0028-70 |
| Proprietary Name | Stavudine |
| Package Description | 30 CAPSULE in 1 BOX, UNIT-DOSE (0179-0028-70) |
| Product NDC | 0179-0028 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Stavudine |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20100127 |
| Marketing Category Name | ANDA |
| Labeler Name | KAISER FOUNDATION HOSPITALS |
| Substance Name | STAVUDINE |
| Strength Number | 40 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |